International expansion Paragon Genomics has active partnering and distribution agreements to expand CleanPlex in the UK, Ireland, and Italy, signaling a clear channel strategy and potential to upsell regional distributors with additional products and services.

Clinical and surveillance demand The ongoing evolution of SARS-CoV-2 panels and emerging variant add-ons indicates sustained demand for targeted enrichment solutions in clinical research, diagnostics, and epidemiological surveillance, presenting cross-sell opportunities to expand CleanPlex adoption.

Collaborative partnerships Recent collaborations with Biosecure ID, Devyser AB, and Singular Genomics suggest a favorable ecosystem for co-marketing and bundled solutions, offering avenues to propose integrated workflows and joint go-to-market initiatives.

NGS workflow efficiency Paragon’s CleanPlex technology addresses throughput and efficiency bottlenecks in targeted sequencing, presenting a strong value proposition for laboratories scaling panels, increasing run capacity, and reducing time-to-result.

Growing financial signals With a mid-market revenue range and verified fundraising activity, there is an opportunity to approach strategic investors and distribution partners for larger cumulative orders, channel financing, or co-development funding to accelerate market penetration.